Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL
Status: | Active, not recruiting |
---|---|
Conditions: | Ocular |
Therapuetic Areas: | Ophthalmology |
Healthy: | No |
Age Range: | Any |
Updated: | 2/10/2017 |
Start Date: | March 2015 |
End Date: | December 2019 |
A Prospective, Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber Intraocular Lens (IOL)
To evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL
following cataract surgery.
following cataract surgery.
The objective of this post approval safety study is to evaluate the incidence of IOL
vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery at up to
three years post implantation.
vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery at up to
three years post implantation.
Inclusion Criteria:
- Subjects who are able and willing to comply with the follow-up schedule
- Subjects must have a clinically documented diagnosis of age-related cataract that is
considered amenable to treatment with standard phacoemulsification/extracapsular
cataract extraction
- Subjects must require a lens power from 4 to 33 D
- Subjects must have a Best Corrected Visual Acuity (BCVA) equal to or worse than
20/40, with or without a glare source
Exclusion Criteria:
- Subjects with any anterior segment pathology in the study eye likely to increase the
risk of complications from phacoemulsification cataract surgery
- Subjects with associated ocular conditions which could affect the stability of the
IOL
- Subjects with clinically significant irregular corneal astigmatism in the study eye
We found this trial at
1
site
Click here to add this to my saved trials